Discussion
ICBs
CERVICAL CANCER, DER
The scientometric analysis in this study demonstrated the fast development of immunotherapies in cervical cancer. The publication and citation numbers of this field have kept growing in recent years. The United States and China were the two countries with the most publications. van der Burg SH was the author with the highest number of publications and citations. Santin AD had the highest co-citations, followed by Tewari KS, and van der Burg SH. There were seven clinical trials on the list of the top 10 references with the highest co-citations, in which three trials were associated with ICBs such as Pembrolizumab and Nivolumab, two trials were about vaccine therapies, one trial was about tumor-infiltrating T cells, and one trial was associated with Bevacizumab. And some necessary discussions were also made, followed by the analysis results. Co-occurrence analysis of keywords reflected the core topic of our study, immunotherapies in cervical cancer caused by HPV. And the timeline view of keywords showed the development and the research hotspots of the field along with time. Burst analysis of keywords also detected the hotspots of this field. And it showed that the research of ICBs such as Nivolumab and Pembrolizumab and their related fields were the main topics in recent years.The analysis of clinical trials in this study also represented some same trends and foci as the scientometric analysis. There are four main kinds of immunotherapies in the current treatment of cervical cancer, including ICBs, Vaccines, ACT, and antibody-drug conjugate (ADC). The distribution of the common treatment modes showed that combined therapies are gradually becoming the new trend, especially ICBs combined with chemotherapy, chemoradiotherapy, and other immunotherapies. Besides, clinical trials of some important immunotherapeutic drugs were also analyzed. Based on the analysis, the common treatment modes and their key drugs were to be further discussed (
